Company / Interest Expense
Sarepta Therapeutics Interest Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$1.9M
FY2025
5-year range
-$22.0M / $63.5M
FY2021-FY2025
Trend
+110.3%
vs FY2024
Sector context
#36 of 44
Health Care
What the data says
Sarepta Therapeutics's interest expense of $2M is lower than 82% of companies in the Health Care sector (FY2025). Interest Expense has fluctuated over the past 10 years, ranging from -$22M in FY2023 to $64M in FY2021.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of -43.7%.
Increased from -$22M to $2M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -68.4%
- 5-Year CAGR
- -43.7%
- 10-Year CAGR
- -
Sector benchmark
Top 18% in Health CareTop 18% of 44This company $1.9M Sector average $291.0M
▼
-99.3% below sector average
Key checks
Key Insights
- 5-year CAGR of -43.7%, indicating a declining trend.
- In FY2025, interest expense increased 110.3% year-over-year.
- Ranks #36 out of 44 companies in the Health Care sector.
- Peak interest expense was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.9M | +110.3% |
| FY2024 | -$18.4M | +16.4% |
| FY2023 | -$22.0M | -136.7% |
| FY2022 | $59.9M | -5.6% |
| FY2021 | $63.5M | +88.5% |
| FY2020 | $33.7M | +481.1% |
| FY2019 | $5.8M | -82.8% |
| FY2018 | $33.7M | +481.1% |
| FY2017 | $5.8M | +206.6% |
| FY2016 | $1.9M | +38.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026